why choose us

First received: October 24, 2022

Clinical Trial: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Smoldering Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Selinexor for the Treatment of Patients With Intermediate and High-Risk Smoldering Multiple Myeloma

Brief Summary: Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma.The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes.A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering…

Read more